- Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918
-
In our ongoing efforts to develop CGRP receptor antagonists for the treatment of migraine, we aimed to improve upon telecagepant by targeting a compound with a lower projected clinical dose. Imidazoazepanes were identified as potent caprolactam replacemen
- Paone, Daniel V.,Nguyen, Diem N.,Shaw, Anthony W.,Burgey, Christopher S.,Potteiger, Craig M.,Deng, James Z.,Mosser, Scott D.,Salvatore, Christopher A.,Yu, Sean,Roller, Shane,Kane, Stefanie A.,Selnick, Harold G.,Vacca, Joseph P.,Williams, Theresa M.
-
scheme or table
p. 2683 - 2686
(2011/06/20)
-
- CARBOXAMIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
-
Compounds of formula I: I wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as mi
- -
-
Page/Page column 52
(2009/01/24)
-
- CGRP RECEPTOR ANTAGONISTS
-
Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
- -
-
Page/Page column 114
(2010/11/08)
-